Elongase gene, and process for the preparation of polyunsaturated fatty acids 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
US2008160054 A1 2008-07-03 [US20080160054]US8933300 B2 2015-01-13 [US8933300] / 2008-07-032015-01-13
申请号/申请日
2007US-11682269 / 2007-03-05
发明人
HEINZ ERNST;ZANK THORSTEN;ZÄHRINGER ULRICH;LERCHL JENS;RENZ ANDREAS;
申请人
BASF;
主分类号
IPC分类号
A01H-005/00A01K-067/027A23K-001/16A23L-001/30A61K-008/30A61K-008/36A61K-008/92A61K-031/201A61K-031/202A61P-003/02A61P-003/06A61P-009/10A61P-029/00C07H-021/04C07K-016/40C11C-003/00C12N-001/20C12N-009/00C12N-009/10C12N-015/09C12N-015/54
摘要
(US8933300) The invention relates to novel elongase genes with the sequences stated in sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or their homologs, derivatives or analogs, to a gene construct comprising this gene or its homologs, derivatives and analogs, and to its use.  The invention also relates to vectors or transgenic organisms comprising an elongase gene with the sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or its homologs, derivatives and analogs.  The invention furthermore relates to the use of the elongase gene sequences alone or in combination with further elongases and/or further fatty acid biosynthesis genes.  The present invention relates to a novel elongase gene with the sequence SEQ ID NO:1 or its homologs, derivatives and analogs.  Furthermore, the invention relates to a process for the preparation of polyunsaturated fatty acids and to a process for introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids.  Moreover, the invention relates to an oil and/or a fatty acid preparation with a higher content of polyunsaturated fatty acids with at least two double bonds and/or a triacylglycerol preparation with a higher content of polyunsaturated fatty acids with at least two double bonds.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2000DE-1005973 2000-02-09 2000DE-1023893 2000-05-17 2000DE-1063387 2000-12-19 2001WO-EP01346 2001-02-08 2002US-10182634 2002-07-31 2007US-11682269 2007-03-05
主权利要求
(US8933300) We claim: 1.  A gene construct having a heterologous promoter or a vector comprising an isolated nucleic acid sequence encoding a polypeptide functionally linked to one or more regulatory signals, wherein the isolated nucleic acid sequence comprises a derivative of SEQ ID NO: 1, and the polypeptide elongates C18-fatty acids with at least two double bonds in the fatty acid molecule, and wherein the polypeptide is selected from the group consisting of i) polypeptides having the amino acid sequence of SEQ ID NO:2, and   ii) polypeptides having an amino acid sequence with at least 80% identity at the amino acid level with SEQ ID NO:2 having elongase activity. 2. The gene construct or vector of claim 1, wherein the isolated nucleic acid sequence is derived from Physcomitrella. 3. The gene construct or vector as claimed in claim 1, further comprising a nucleic acid sequence which encodes a fatty acid biosynthesis gene. 4. The gene construct or vector as claimed in claim 2, wherein the nucleic acid which encodes a fatty acid biosynthesis gene is selected from the group consisting of: DELTA 19-, DELTA 17-, DELTA 15-, DELTA 12-, DELTA 9-, DELTA 8-, DELTA 6-, DELTA 5-, DELTA 4-desaturase, hydroxylases, DELTA 12-acetylenase, acyl-ACP thioesterases, beta -ketoacyl-ACP synthases and beta -ketoacyl-ACP reductases. 5. An organism other than a human comprising the isolated nucleic acid sequence introduced by the gene construct or vector as claimed in claim 1. 6. The organism as claimed in claim 5, wherein the organism is a microorganism, yeast or a plant. 7. The organism as claimed in claim 5, wherein the organism is a transgenic plant. 8. A process for the preparation of a PUFA, which comprises culturing an organism comprising the isolated nucleic acid sequence introduced by the gene construct or vector of claim 1 under conditions under which PUFAs are formed in the organism. 9. The process as claimed in claim 8, wherein the PUFA is a C18-fatty acid molecule with at least two double bonds in the fatty acid molecule. 10. The process as claimed in claim 9, wherein the C18-fatty acid molecule is isolated from the organism in the form of an oil, lipid or a free fatty acid. 11. The process as claimed in claim 8, wherein the organism is a microorganism, an animal or a plant. 12. The process as claimed in claim 8, wherein the organism is a transgenic plant. 13. The process as claimed in claim 8, wherein the C18-fatty acid is a fatty acid with three double bonds in the molecule. 14. A kit comprising the gene construct or vector comprising said isolated nucleic acid sequence of claim 1. 15. The gene construct or vector as claimed in claim 1 wherein the isolated nucleic acid sequence is derived from a plant. 16. A gene construct of claim 1, wherein gene expression is enhanced by said regulatory signals. 17. The gene construct or vector of claim 1, wherein the polypeptide having at least 80% identity at the amino acid level with SEQ ID NO:2 contains motifs FLHVYHH, corresponding to amino acids 158 to 164 of SEQ ID NO: 2 which is optionally substituted in the first, third, fourth and fifth positions position with T, Q, W, L respectively, LMYAYYF, corresponding to amino acids 196 to 202 of SEQ ID NO: 2 which is optionally substituted in the first, fourth, fifth, and sixth, position with I, M, H, F respectively, and FGNFYVQ, corresponding to amino acids 268 to 274 of SEQ ID NO: 2 which is optionally substituted in the second and seventh position with L. 18. The gene construct or vector of claim 1, wherein the polypeptide is selected from the groups consisting of i) polypeptides having the amino acid sequence of SEQ ID NO:2, and   ii) polypeptides having an amino acid sequence with at least 95% identity at the amino acid level with SEQ ID NO:2 having elongase activity. 19. The gene construct or vector of claim 1, wherein the polypeptide elongates 6,9-octadecadienoic acid, linoleic acid, linolenic acid, alpha - or gamma -linolenic acid, pinolenic acid or stearidonic acid.
法律状态
(US8933300) LEGAL DETAILS FOR US2008160054  Actual or expected expiration date=2026-03-12    Legal state=ALIVE    Status=GRANTED     Event publication date=2007-03-05  Event code=US/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=US US11682269  Application date=2007-03-05  Standardized application number=2007US-11682269     Event publication date=2008-07-03  Event code=US/A1  Event type=Examination events  Application published  Publication country=US  Publication number=US2008160054  Publication stage Code=A1  Publication date=2008-07-03  Standardized publication number=US20080160054     Event publication date=2015-01-13  Event code=US/B2  Event indicator=Pos  Event type=Event indicating In Force  Granted patent as second publication  Publication country=US  Publication number=US8933300  Publication stage Code=B2  Publication date=2015-01-13  Standardized publication number=US8933300     Event publication date=2015-01-13  Event code=US/354  Event indicator=Pos  Event type=Event indicating In Force  Event type=Extension of term of duration of protection  Patent term extension under  35 U.S.C 154(b) until/for:  Number of days of extension=1858
专利类型码
A1B2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部